<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24173190</article-id>
      <article-id pub-id-type="pmc">3798361</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20132070</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Case report of cutaneous histiocytic sarcoma: diagnostic and therapeutic
dilemmas<sup><xref ref-type="fn" rid="fn03">*</xref></sup></article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Relato de um caso de sarcoma histioc&#xED;tico cut&#xE2;neo: dilemas diagn&#xF3;sticos
e terap&#xEA;uticos</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Trevisan</surname>
            <given-names>Fl&#xE1;via</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Xavier</surname>
            <given-names>Celia Antonia</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Clovis Antonio Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cattete</surname>
            <given-names>Fernanda Gomes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stock</surname>
            <given-names>Fab&#xED;ola Schauffler</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martins</surname>
            <given-names>Marcella Ledo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, resident of Dermatology, Faculty of Medicine of Jundiai (FMJ) -
Jundia&#xED; (SP), Brazil.</aff>
      <aff id="aff02"><label>2</label> MS, adjunct professor of Dermatology, Faculty of Medicine of Jundiai
(FMJ) - Jundia&#xED; (SP), Brazil.</aff>
      <aff id="aff03"><label>3</label> PhD, adjunct professor of Pathology, Faculty of Medicine of Jundiai
(FMJ) - Jundia&#xED; (SP), Brazil.</aff>
      <author-notes>
        <corresp id="c01"> MAILING ADDRESS: Fl&#xE1;via Trevisan, Rua Francisco Telles, 250 - Vila
Arens, 13202-250 - Jundia&#xED; - SP, Brazil, E-mail:
<email>flaviatrevisan1@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>5</issue>
      <fpage>807</fpage>
      <lpage>810</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>8</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>9</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Histiocytic sarcoma is a rare hematologic malignant neoplasia originating from
histiocytic or dendritic cell clones. The lesions may be in nodal or extranodal
sites, most commonly in the gastrointestinal tract. A small number of cases presents
as unique cutaneous lesions. The definitive diagnosis is made by positivity for the
immunohistochemical markers CD163, CD68, CD4 and lysozyme. The treatment is
controversial, often with combined systemic chemotherapy. This is a case of cutaneous
histiocytic sarcoma in an 82-year-old patient presenting two nodular lesions in the
breast and right arm which were treated with simple excision and multidisciplinary
follow-up, avoiding aggressive management and exhaustive investigations. Although
most studies report aggressive evolution, the patient had good and stable clinical
status during the twelve-month follow-up period.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Sarcoma histioc&#xED;tico &#xE9; uma rara entidade neopl&#xE1;sica maligna hematol&#xF3;gica originada de
clones celulares dendr&#xED;ticos ou histiocit&#xE1;rios. As les&#xF5;es podem ser nodais ou
extranodais, mais comumente no trato gastrintestinal. Um pequeno n&#xFA;mero de casos
apresenta les&#xF5;es cut&#xE2;neas exclusivas. O diagn&#xF3;stico definitivo &#xE9; feito pela
positividade dos marcadores imunohistoqu&#xED;micos CD163, CD68, CD4 e lisozima. O
tratamento &#xE9; controverso, geralmente com quimioterapia combinada sist&#xEA;mica. Este &#xE9; um
caso de sarcoma histioc&#xED;tico cut&#xE2;neo em uma paciente de 82 anos apresentando duas
les&#xF5;es nodulares na mama e bra&#xE7;o direitos, tratadas com ex&#xE9;rese simples e seguimento
multidisciplinar, evitando-se condutas intempestivas e investiga&#xE7;&#xF5;es exaustivas.
Apesar de a maioria dos estudos relatar evolu&#xE7;&#xE3;o agressiva, a paciente apresenta
quadro cl&#xED;nico bom e est&#xE1;vel no per&#xED;odo de doze meses de seguimento.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Histiocytic disorders, malignant</kwd>
        <kwd>Histiocytic sarcoma</kwd>
        <kwd>Immunohistochemistry</kwd>
        <kwd>Sarcoma</kwd>
        <kwd>Therapeutics</kwd>
        <kwd>Treatment outcome</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>The histiocytic sarcoma (HS) is a hematologic malignancy with histiocytic
differentiation classified in a group of neoplasms of dendritic and histiocytic
cells.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r04">4</xref></sup> With only a few hundred cases reported, the HS affects
adults in the fifth decade of life.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
Often synchronous or metachronous with other hematologic malignancies, especially acute
myeloid leukemia and follicular lymphoma.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r03">3</xref></sup>
</p>
      <p>Clinically, the HS can affect lymph nodes, gastrointestinal tract, skin, bone marrow,
spleen and central nervous system.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r03">3</xref></sup> The symptoms depend on the involved
organ. Skin is affected in almost 7% of the cases, and lesions are described as
maculopapular rash, areas of soft consistence on palpation or subcutaneous nodules with
central necrosis and ulcers.<sup><xref ref-type="bibr" rid="r05">5</xref></sup> The
differential diagnosis includes cutaneous lymphomas, carcinomas, melanoma, benign
histiocytic prolifera tive processes, granulocytic sarcoma and extranodular myeloid
tumor.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>Histologically, there is a perivascular and periadnexal dermal and subcutaneous
histiocytic infiltrate, with cell bundles in some areas. Neoplastic cells are
polymorphic, with large and vesicular nuclei, prominent nucleoli and eosinophilic and
foamy cytoplasm. Hemophagocytosis may occur and the presence of mitosis is
variable.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup> Immunohistochemistry is positive for histiocytic markers
such as CD163 and CD68 (<xref ref-type="table" rid="t01">Table 1</xref>).<sup><xref ref-type="bibr" rid="r01">1</xref></sup> CD4, a known marker of T lymphocytes, can
also be expressed in cells of the myelomonocytic and histiocytic lineages and is
therefore positive in histiocytic sarcoma, although with low specificity. There is also
positivity for lysozyme, fascin and CD11c, but there is no expression of markers for B
or T cells, CD1a, S100 and epithelial markers.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r03">3</xref></sup> Rearrangement studies are
controversial and in most cases are not necessary.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Bone marrow biopsy is indicated in case of cytopenia or evidence
of hemophagocytosis<sup><xref ref-type="bibr" rid="r03">3</xref></sup> and acute myeloid
leukemia should always be excluded.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>TABLE 1</label>
        <caption>
          <p>Immunohistochemical markers in histiocytic sarcoma</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Positive markers </bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Meaning </bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Negative markers </bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Meaning </bold>
              </td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">CD4 </td>
              <td rowspan="1" colspan="1">Dendritic and Langerhans cells </td>
              <td rowspan="1" colspan="1">AE1-AE3 </td>
              <td rowspan="1" colspan="1">Cytokeratins </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CD45 </td>
              <td rowspan="1" colspan="1">Common leukocyte antigen </td>
              <td rowspan="1" colspan="1">Melan-A </td>
              <td rowspan="1" colspan="1">Melanoma antigens </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CD68 </td>
              <td rowspan="1" colspan="1">Histiocytes </td>
              <td rowspan="1" colspan="1">CD1a </td>
              <td rowspan="1" colspan="1">Langerhans cells </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CD163 </td>
              <td rowspan="1" colspan="1">Histiocytes </td>
              <td rowspan="1" colspan="1">CD3 </td>
              <td rowspan="1" colspan="1">T lymphocytes </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CD11c </td>
              <td rowspan="1" colspan="1">Dendritic cells </td>
              <td rowspan="1" colspan="1">CD20 </td>
              <td rowspan="1" colspan="1">Lymphocytes and epithelial cells </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Lysozyme<xref ref-type="table-fn" rid="t01-fn01">*</xref></td>
              <td rowspan="1" colspan="1">Myeloid antigens </td>
              <td rowspan="1" colspan="1">CD23 </td>
              <td rowspan="1" colspan="1">B lymphocytes </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Fascin </td>
              <td rowspan="1" colspan="1">Dendritic cells </td>
              <td rowspan="1" colspan="1">CD20 </td>
              <td rowspan="1" colspan="1">B lymphocytes </td>
            </tr>
            <tr>
              <td rowspan="6" colspan="1"/>
              <td rowspan="6" colspan="1"/>
              <td rowspan="1" colspan="1">CD25 </td>
              <td rowspan="1" colspan="1">Mastocytes </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CD30 </td>
              <td rowspan="1" colspan="1">B and T activated lymphocytes </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">CD34 </td>
              <td rowspan="1" colspan="1">Hematopoietic progenitor cells </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">MAC387<xref ref-type="table-fn" rid="t01-fn02">**</xref></td>
              <td rowspan="1" colspan="1">Macrophages </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Fator XIIIa<xref ref-type="table-fn" rid="t01-fn02">**</xref></td>
              <td rowspan="1" colspan="1">Dermal dendrocytes </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">S-100<xref ref-type="table-fn" rid="t01-fn02">**</xref></td>
              <td rowspan="1" colspan="1">Dendritic cells </td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t01-fn01">
            <label>*</label>
            <p>Granular with accentuation of the Golgi complex;</p>
          </fn>
          <fn id="t01-fn02">
            <label>**</label>
            <p>Focally positive.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>The course is usually aggressive, with worse prognosis when greater than 3.5 cm and on
advanced stage.<sup><xref ref-type="bibr" rid="r01">1</xref></sup> Good progress signals
are the absence of cytopenias and liver abnormalities.<sup><xref ref-type="bibr" rid="r05">5</xref></sup>
</p>
      <p>Little is known about the therapy, with options ranging from surgical excision with or
without radiotherapy in patients with isolated lesions of HS, to systemic combination
chemotherapy regimens used to treat lymphoma (CHOP and ICE) and thalidomide.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>An 82-year-old female patient presented since 15 days prior to consultations two
asymptomatic nodular and crateriform lesions, about 1.0 cm wide, covered with central
keratosis and crust and erythematous-violaceous infiltrated edges in the right arm and
breast (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>). An excisional biopsy of the lesions was made. The histological
diagnosis was of indeterminate malignant neoplasm with deep margins involved and the
immunohistochemical examination was positive for CD68, CD4, CD11c, fascin , CD45, CD163
and lysozyme, factor XIIIa was inconclusive and markers of melanin, B and T cells and
cytokeratin were negative (<xref ref-type="fig" rid="f03">Figures 3</xref>, <xref ref-type="fig" rid="f04">4</xref> and <xref ref-type="fig" rid="f05">5</xref>). The
ultrasonography of soft tissues, breast and axillary lymph nodes and brain and abdomen
CT scans showed no signs of neoplastic disease. Tomography of the chest revealed
multiple bilateral pulmonary nodules, which were stable in sequential scans and
therefore were not biopsied. Other hematological tumors having been excluded, a
diagnosis of primary cutaneous histiocytic sarcoma was made. The management included
observation of excision sites without expanding margins and periodic oncological and
dermatological follow-up. No sign of recurrence was evidenced in the twelve-month
follow-up period.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Histiocytic sarcoma. Crateriform and nodular lesion, 1.0 cm wide, covered by
keratosis and central crust on the medial side of the right arm</p>
        </caption>
        <graphic xlink:href="abd-88-05-0807-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Histiocytic sarcoma. Nodular and crateriform lesion, 1.0cm wide, covered by
keratosis and crust on the right breast</p>
        </caption>
        <graphic xlink:href="abd-88-05-0807-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Undetermined neoplastic cell proliferation in the dermis. (Hematoxylin-eosin,
40x)</p>
        </caption>
        <graphic xlink:href="abd-88-05-0807-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Cytoplasm strongly stained for CD68 in malignant dermal cells.
(Immunohistochemistry for CD68, 100x)</p>
        </caption>
        <graphic xlink:href="abd-88-05-0807-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Fascin stain strongly positive in cells, some forming fascicles.
(Immunohistochemistry for fascin, 100x)</p>
        </caption>
        <graphic xlink:href="abd-88-05-0807-g05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The histiocytic sarcoma is a little discussed entity in dermatology due to the rare
cases that have exclusive cutaneous manifestation. Diagnosis was only possible by
histopathology and confirmed by immunoreactivity of the neoplastic cells for CD163,
CD68, lysozyme and CD4.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup> Therapeutic choices range from simple
excision of the lesions with or without radiotherapy to combined systemic
chemotherapy.<sup><xref ref-type="bibr" rid="r01">1</xref>-<xref ref-type="bibr" rid="r03">3</xref></sup> There are no reports of treatment with intralesional
chemotherapy, but the authors consider this a viable option still under consideration
for small and isolated lesions.</p>
      <p>This report is about a patient of advanced age in good clinical condition, with
cutaneous histiocytic sarcoma diagnosis and no hematological abnormalities or signs of
poor prognosis. Considering that diagnostic investigations and therapeutic options are
still controversial issues in the literature, the dilemma of whether to submit the
patient to further staging procedures and aggressive treatment was a major concern in
the management of this case.</p>
      <p>As the patient had no constitutional symptoms or cytopenias, a bone marrow biopsy was
postponed and the patient was not subjected to high risk invasive procedures. The sites
of lesions are followed clinically at regular intervals of three months. The patient is
in excellent clinical condition, without loss of quality of life and no signs of
recurrence or systemic involvement in the twelve-month follow-up period.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="financial-disclosure">
        <p>Financial Support: None</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of Interests: None.</p>
      </fn>
      <fn id="fn03" fn-type="other">
        <p>* Work performed at the Dermatology Service, Faculty of Medicine of Jundia&#xED; (Servi&#xE7;o
de Dermatologia da Faculdade de Medicina de Jundia&#xED;(FMJ) - Jundia&#xED; (SP), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vos</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Abbondanzo</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Barekman</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Andriko</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Miettinem</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Aguilera</surname>
              <given-names>NS</given-names>
            </name>
          </person-group>
          <article-title>Histiocytic sarcoma: a study of five cases including the histiocyte
marker CD163</article-title>
          <source>Mod Pathol</source>
          <year>2005</year>
          <volume>18</volume>
          <fpage>693</fpage>
          <lpage>704</lpage>
          <pub-id pub-id-type="pmid">15696128</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schnettker</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Salomone</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Valbuena</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous histiocytic sarcoma: report of one case</article-title>
          <source>Rev M&#xE9;d Chile</source>
          <year>2009</year>
          <volume>137</volume>
          <fpage>547</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="pmid">19623422</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="webpage">
          <person-group person-group-type="author">
            <name>
              <surname>Jacobson</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <source>Histiocytic sarcoma</source>
          <date-in-citation content-type="updated">UpToDate, updated in February
2012</date-in-citation>
          <date-in-citation content-type="access-date">cited 2012 Apr 29</date-in-citation>
          <comment>Available from: <ext-link ext-link-type="uri" xlink:href="www.uptodate.com">www.uptodate.com</ext-link></comment>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lahoti</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Natarajan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Karuna</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>D'Souza</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous histiocytic lesions: a clinical dilemma</article-title>
          <source>J Postgrad Med</source>
          <year>2000</year>
          <volume>46</volume>
          <fpage>275</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="pmid">11435656</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Swerdlow</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Campo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Pileri</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Stein</surname>
              <given-names>H</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <etal>et al</etal>
          <source>World Health Organization Classification of Tumours of Haematopoietic and
Lymphoid Tissues</source>
          <edition>4th ed</edition>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>IARC WHO Classification of Tumours</publisher-name>
          <year>2008</year>
          <size units="pages">439 p.</size>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
